Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Efectos adversos severos de los estabilizadores del ánimo: revisión de la literatura
Severe adverse effects of mood stabilizers: a review of the literature
Efeitos adversos graves de estabilizadores de humor: uma revisão da literatura
DOI:
https://doi.org/10.15446/rcciquifa.v51n2.105567Palabras clave:
transtorno bipolar, efectos adversos, efectos adversos graves, carbamazepina, valproato, litio (es)Transtorno bipolar, efeitos adversos, efeitos adversos graves, carbamazepina, valproato, lítio (pt)
Bipolar disorder, adverse effects, serious adverse effects, carbamazepine, valproate, lithium (en)
Descargas
Introducción: el trastorno bipolar TB es una enfermedad crónica y recurrente, según el DSM 5 se clasifica en los subtipos: trastorno bipolar I, trastorno bipolar II, ciclotimia y categorías residuales de formas atípicas que no encajan en los subtipos antes mencionados. La prevalencia del TB tipo I es similar entre hombres y mujeres, mientras que el TB tipo II ocurre con mayor frecuencia en mujeres. Según la Encuesta nacional de salud mental la prevalencia estimada del trastorno bipolar tipo I en Colombia es del 1,9% en los hombres y del 0,6% en las mujeres, para un porcentaje total de 1,3%. La etiología de TB incluye factores genéticos, neuro bioquímicos, neuro anatómicos, así como médicos y ambientales. El tratamiento del trastorno bipolar se puede dividir en dos fases distintas: manejo de un episodio inicial y tratamiento a largo plazo para prevenir recaídas, los fármacos utilizados comúnmente son: litio, antipsicóticos y anticonvulsivantes. Los estabilizadores del estado del ánimo aceptados por la FDA son: litio, carbamazepina, divalproato, y lamotrigina. Una reacción adversa a medicamentos (RAM) se define como cualquier respuesta nociva y no intencionada a un medicamento, constituye una importante causa de morbimortalidad y de aumento de los costes sanitarios. Los sistemas de farmacovigilancia permiten la identificación y prevención de los riesgos asociados al uso de medicamentos. Metodología: se realizó una búsqueda bibliográfica mediante la base de datos PubMed, utilizando términos MeSH. Los criterios de inclusión utilizados fueron: a) Artículos publicados entre el año 2016 y 2021, b) Idioma inglés o español, c) Población a estudio: pacientes con diagnóstico de trastorno bipolar según criterios del DSM. Resultados: se encontró que los efectos adversos severos de los estabilizadores del estado del ánimo como la carbamazepina y el ácido valproico son variados, se pueden presentar manifestaciones cutáneas como el síndrome de Stevens-Johnson, necrólisis epidérmica tóxica; manifestaciones hematológicas como anemia aplásica y manifestaciones hepáticas como lo son la hepatotoxicidad e hiperamonemia.
Introduction: Bipolar disorder TB is a chronic and recurrent disease, according to DSM 5 it is classified into subtypes: bipolar I disorder, bipolar II disorder, cyclothymia and residual categories of atypical forms that do not fit into aforementioned subtypes. Prevalence of type I TB is similar between men and women, while type II TB occurs more frequently in women. According to the National Mental Health Survey, estimated prevalence of type I bipolar disorder in Colombia is 1.9% in men and 0.6% in women, for a total percentage of 1.3%. Etiology of TB includes genetic, neuro biochemical, neuro anatomical, as well as medical and environmental factors. Treatment of bipolar disorder can be divided into two phases: management of an initial episode and long-term treatment to prevent relapses, drugs normally used are: Lithium, antipsychotics and anticonvulsants. Mood stabilizers accepted by FDA are: Lithium, carbamazepine, divalproex, and lamotrigine. An adverse drug reaction (ADR) is defined as any harmful and unintended response to a drug, it constitutes a major cause of morbidity and mortality and increased healthcare costs. Pharmacovigilance systems allow identification and prevention of risks associated with use of drugs. Methodology: A graphic search was performed using PubMed database, using MeSH terms. Inclusion criteria used were: a) Articles published between 2016 and 2021, b) English or Spanish language, c) Study population: Patients with a diagnosis of Bipolar Disorder according to DSM criteria. Results: It was found that severe adverse effects of mood stabilizers such as carbamazepine and valproic acid are varied, skin manifestations such as Stevens-Johnson´s syndrome, toxic epidermalnecrolysis can occur; Hematological manifestations such as aplastic anemia and hepatic manifestations such as hepatotoxicity and hyperammonemia.
Introdução: o transtorno bipolar TB é uma doença crônica e recorrente, segundo o DSM 5 é classificada em subtipos: transtorno bipolar I, transtorno bipolar II, ciclotimia e categorias residuais de formas atípicas que não se enquadram nos subtipos mencionados. A prevalência de TB tipo I é semelhante entre homens e mulheres, enquanto a TB tipo II ocorre com mais frequência em mulheres. De acordo com a Pesquisa Nacional de Saúde Mental, a prevalência estimada de transtorno bipolar tipo I na Colômbia é de 1,9% nos homens e 0,6% nas mulheres, para um percentual total de 1,3%. A etiologia da TB inclui fatores genéticos, neuro-bioquímicos, neuro-anatômicos, médicos e ambientais. O tratamento do transtorno bipolar pode ser dividido em duas fases distintas: manejo de um episódio inicial e tratamento de longo prazo para prevenção de recidivas, os medicamentos comumente utilizados são: lítio, antipsicóticos e anticonvulsivantes. Os estabilizadores de humor aceitos pela FDA são: lítio, carbamazepina, divalproex e lamotrigina. Uma reação adversa a medicamento (ADR) é definida como qualquer resposta prejudicial e não intencional a um medicamento, é uma das principais causas de morbidade e mortalidade e aumento dos custos de saúde. Os sistemas de farmacovigilância permitem a identif icação e prevenção dos riscos associados ao uso de medicamentos. Metodologia: foi realizada pesquisa bibliográfica na base de dados PubMed, utilizando termos MeSH. Os critérios de inclusão utilizados foram: a) Artigos publicados entre 2016 e 2021, b) Língua inglesa ou espanhola, c) População do estudo: Pacientes com diagnóstico de Bipolar Desordem de acordo com os critérios do DSM. Resultados: verificou-se que os efeitos adversos graves dos estabilizadores do humor como a carbamazepina e o ácido valpróico são variados, podendo ocorrer manifestações cutâneas como a síndrome de Stevens-Johnson, podendo ocorrer necrólise epidérmica tóxica; Manifestações hematológicas como anemia aplástica e manifestações hepáticas como hepatotoxicidade e hiperamonemia.
Referencias
R.S. McIntyre, M. Berk, E. Brietzke, B.I. Goldstein, A.H. López-Jaramillo, R.B. Mansur, Bipolar disorders, Lancet, 396(10265), 1841-1856 (2020).
A.F. Carvalho, J. Firth, E. Vieta, Bipolar disorder, New Engl. J Med., 383(1), 58-66 (2020). R.S. DOI: https://doi.org/10.1056/NEJMra1906193
McIntyre, M. Berk, E. Brietzke, B.I. Goldstein, C. López-Jaramillo, L.V. Kessing, Bipolar disorders, Lancet, 396(10265), 1841-1856 (2020). DOI: https://doi.org/10.1016/S0140-6736(20)31544-0
M.A. Jiménez-Arriero, T. Palomo-Álvarez, R. Rodríguez-Jiménez, Fundamentos de Psiquiatría: Bases científicas para el manejo clínico, Editorial Médica Panamericana, Buenos Aires, 2015, pp. 144-148.
A. Joshi, A. Bow, M. Agius, M. (2019). Pharmacological therapies in bipolar disorder: A review of current treatment options, Psychiatria Danubina, 31(Suppl 3), 595-603 (2019).
O.M. Dean, E. Gliddon, T.E. Van Rheenen, F. Giorlando, S.K. Davidson, M. Kaur, An update on adjunctive treatment options for bipolar disorder, Bipolar disorders, 20(2), 87-96 (2018). DOI: https://doi.org/10.1111/bdi.12601
E. Montané, J. Santesmases, Reacciones adversas a medicamentos, Medicina Clínica, 154(5), 178-184 (2020). DOI: https://doi.org/10.1016/j.medcli.2019.08.007
Encuesta Nacional de Salud Mental 2015, Ministerio de Salud y Protección Social, 2015, Cap. 4, p. 236.
E. Vieta, M. Berk, T.G. Schulze, A.F. Carvalho, T. Suppes, J.R. Calabrese, K. Gao, K.W. Miskowiak, I. Grande, Bipolar disorders, Nature Reviews, 4, 18008 (2018). DOI: https://doi.org/10.1038/nrdp.2018.8
C.H. Chen, S.K. Lin, Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes, BMC Psychiatry, 12, 47 (2012). DOI: https://doi.org/10.1186/1471-244X-12-47
J.G. Small, M.H. Klapper, V. Milstein, J.J. Kellams, M.J. Miller, J.D. Marhenke, I.F. Small, Carbamazepine compared with lithium in the treatment of mania, Arch. Gen. Psychiatry, 48(10), 915-921 (1991). DOI: https://doi.org/10.1001/archpsyc.1991.01810340047006
S. Englisch, M. Zink, Treatment-resistant schizophrenia: Evidence-based strategies, Mens Sana Monogr., 10(1), 20-32 (2012). DOI: https://doi.org/10.4103/0973-1229.91588
J. Winkelmann, R.P. Allen, B. Högl, Y. Inoue, W. Oertel, A.V. Salminen, J.W. Winkelman, C. Trenkwalder, C. Sampaio, Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice, Mov. Disord., 33(7), 1077-1091 (2018). DOI: https://doi.org/10.1002/mds.27260
M. Bialer, Chemical properties of antiepileptic drugs (AEDs), Adv. Drug Deliv. Rev., 64(10), 887–895 (2012). 15. Z. Tolou-Ghamari, M. Zare, J.M. Habibabadi, et al., A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012, J. Res. Med. Sci., 18(Suppl 1), S81-S85 (2013). DOI: https://doi.org/10.1016/j.addr.2011.11.006
L. Bertilsson, Clinical pharmacokinetics of carbamazepine, Clin. Pharmacokinet., 3(2), 128-143 (1978). DOI: https://doi.org/10.2165/00003088-197803020-00003
P.J. Sims, M. Burton, L. Shaw, et al., Applied pharmacokinetics and pharmacodynamics principles of therapeutic drug monitoring, Lippincott Williams & Wilkins, Baltimore (MD), 2006.
H.-Z. Bu, P. Kang, A.J. Deese, et al., Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine, Drug Metab. Dispos., 33(12), 1920-1924 (2005).
R.E. Pearce, G.R. Vakkalagadda, J.S. Leeder, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites, Drug Metab. Dispos., 30(11), 1170-1179 (2002). DOI: https://doi.org/10.1124/dmd.30.11.1170
R. Saini, S. Saini, R.S. Sugandha, Pharmacogenetics: the future medicine, J. Adv. Pharm. Technol. Res., 1(4), 423-424 (2010). DOI: https://doi.org/10.4103/0110-5558.76443
A.B. Kowski, F. Weissinger, V. Gaus, et al., Specific adverse effects of antiepileptic drugs – a true-to-life monotherapy study, Epilepsy Behav., 5, 150-157 (2016). DOI: https://doi.org/10.1016/j.yebeh.2015.11.009
J.-C. Roujeau, J.P. Kelly, L. Naldi, et al., Medication use and the risk of StevensJohnson syndrome or toxic epidermal necrolysis, N. Engl. J. Med., 333(24), 1600-1608 (1995). DOI: https://doi.org/10.1056/NEJM199512143332404
M. Mockenhaupt, C. Viboud, A. Dunant, et al., Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study, J. Invest. Dermatol., 128(1), 35-44 (2008). DOI: https://doi.org/10.1038/sj.jid.5701033
M.J. Brodie, P.W. Overstall, L. Giorgi, Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK lamotrigine elderly study group, Epilepsy Res., 37(1), 81-87 (1999). DOI: https://doi.org/10.1016/S0920-1211(99)00039-X
T.J. Bommersbach, M.I. Lapid, J.G. Leung, et al., Management of psychotropic drug-induced DRESS syndrome: a systematic review, Mayo Clin. Proc., 91(6), 787-801 (2016). DOI: https://doi.org/10.1016/j.mayocp.2016.03.006
B. Błaszczyk, W. Lasoń, S.J. Czuczwar, Antiepileptic drugs and adverse skin reactions: an update, Pharmacol. Rep., 67(3), 426-434 (2015). DOI: https://doi.org/10.1016/j.pharep.2014.11.009
C. Bénichou, Criteria of drug-induced liver disorders. Report of an international consensus meeting, J. Hepatol., 11(2), 272-276 (1990). 28. R.R.S. Hussein, R.H. Soliman, A.M.A. Ali, et al., Effect of antiepileptic drugs on liver enzymes science direct, Beni-Suef Univ. J. Basic. Appl. Sci., 2(2), 14-19 (2013). DOI: https://doi.org/10.1016/j.bjbas.2013.09.002
G.M. Forbes, G.P. Jeffrey, K.B. Shilkin, et al., Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome, Gastroenterology, 102(4), 1385-1388 (1992). DOI: https://doi.org/10.1016/0016-5085(92)90780-3
A. Pandit, T. Sachdeva, P. Bafna, Drug-induced hepatotoxicity: a review, J. Appl. Pharm. Sci., 02(05), 233-243 (2011).
A. Asadi-Pooya, M. Sperling, Antiepileptic drugs: a clinician’s manual, Oxford University Press, New York (NY), 2009, pp. 165-170. DOI: https://doi.org/10.1093/oso/9780195368215.003.0018
N.S. Young, P. Scheinberg, R.T. Calado, Aplastic anemia, Curr. Opin. Hematol., 15(3), 162-168 (2008).
K.B. Handoko, P.C. Souverein, T.P. Van Staa, et al., Risk of aplastic anemia in patients using antiepileptic drugs, Epilepsia, 47(7), 1232-1236 (2006). DOI: https://doi.org/10.1111/j.1528-1167.2006.00596.x
N.S. Young, P. Scheinberg, R.T. Calado, Aplastic anemia, Curr. Opin. Hematol., 15(3), 162-168 (2008). DOI: https://doi.org/10.1097/MOH.0b013e3282fa7470
J.C. Yáñez-Rubal, J. Estévez-Rodríguez, M.C. Crespo-López, et al., Carbamazepine-induced aplastic anaemia: a case report, Rev. Neurol., 35(7), 647-649 (2002). DOI: https://doi.org/10.33588/rn.3507.2001003
I. Koutsavlis, M. Lasebai, Dose-dependent carbamazepine-induced agranulocytosis following bariatric surgery (sleeve gastrectomy): a possible mechanism, Bariatric Surg, Pract, Patient Care, 10(3), 130-134 (2015). DOI: https://doi.org/10.1089/bari.2015.0020
T. Tagawa, K. Sumi, R. Uno, et al., Pure red cell aplasia during carbamazepine monotherapy, Brain Dev., 19(4), 300-302 (1997). DOI: https://doi.org/10.1016/S0387-7604(97)00580-9
A. Verrotti, A. Scaparrotta, S. Grosso, et al., Anticonvulsant drugs and hematological disease, Neurol. Sci., 35(7), 983-993 (2014). DOI: https://doi.org/10.1007/s10072-014-1701-0
M. Romoli, P. Mazzocchetti, R. D’Alonzo, et al., Valproic acid and epilepsy: From molecular mechanisms to clinical evidences, Curr. Neuropharmacol., 17(10), 926-946 (2019). DOI: https://doi.org/10.2174/1570159X17666181227165722
M. Buoli, M. Serati, A. Botturi, A.C. Altamura, The risk of thrombocytopenia during valproic acid therapy: A critical summary of available clinical data, Drugs R. D., 18(1), 1-5 (2018). DOI: https://doi.org/10.1007/s40268-017-0224-6
G. Zaccara, A. Messori, F. Moroni, Clinical pharmacokinetics of valproic acid – 1988, Clinical Pharmacokin., 15, 367-389 (1988). DOI: https://doi.org/10.2165/00003088-198815060-00002
A. Cipriani, K. Reid, A.H. Young, K. Macritchie, J. Geddes, Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder, Cochrane Database of Systematic Reviews, 2013, CD003196 (2013).
R. Gugler, E. Gerd, Clinical Pharmacokinetics of Valproic Acid, ADIS Press Australasia Pty Ltd., 1980.
M. Bourin, F. Chenu, M. Hascoët, The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers, Curr. Drug Targets, 10(11), 1052-1060 (2009). 45. A. Jain, I. Haque, V. Tayal, V. Roy, Valproic acid-induced acute pancreatitis, Indian J. Psychiatry, 61, 421-*422 (2019).
M. Rashid, A. Kashyap, K. Undela, Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies, Int. J. Dermatol., 58, 10141022 (2019). DOI: https://doi.org/10.1111/ijd.14411
R. Pérez-Esparza, N. Oñate-Cadena, J. Ramírez-Bermúdez, M. Espínola-Nadurille, Valproate-induced hyperammonemic encephalopathy presenting as catatonia, Neurologist, 23(2), 51-52 (2018).
C. Lewis, G.E. Tesar, R. Dale, Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders, Psychosomatics, 58(4), 415- 420 (2017). 49. M. Schou, Lithium in psychiatric therapy and prophylaxis, J. Psychiatr. Res., 6, 67-95 (1968).
A.S.H. Leung, Lithium carbonate, Can. Psychiatric Assoc. J., 15(2), 189-200 (1970). 51. R.P. Hullin, J.C. Swinscoe, R. McDonald, G.A. Dransfield, Metabolic balance studies on the effect of lithium salts in manic-depressive psychosis, Br. J. Psychiatry, 114(517), 1561-1573 (1968).
R. Epstein, L. Grant, M. Herjanic, G. Winokur, Urinary excretion of lithium in mania, J. Am. Med. Assoc., 192(5), 409 (1965). 53. K. Greenspan, R. Green, J. Durell, Retention and distribution patterns of lithium, a pharmacological tool in studying the pathophysiology of manicdepressive psychosis, Am. J. Psychiatry, 125(4), 512-519 (1968).
A. Cipriani, K. Reid, A.H. Young, K. Macritchie, J. Geddes, Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder, Cochrane Database of Systematic Reviews, 2013, CD003196 (2013). DOI: https://doi.org/10.1002/14651858.CD003196.pub2
R. Gugler, E. Gerd, Clinical Pharmacokinetics of Valproic Acid, ADIS Press Australasia Pty Ltd., 1980.
M. Bourin, F. Chenu, M. Hascoët, The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers, Curr. Drug Targets, 10(11), 1052-1060 (2009). DOI: https://doi.org/10.2174/138945009789735138
A. Jain, I. Haque, V. Tayal, V. Roy, Valproic acid-induced acute pancreatitis, Indian J. Psychiatry, 61, 421-*422 (2019). 46. M. Rashid, A. Kashyap, K. Undela, Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies, Int. J. Dermatol., 58, 10141022 (2019). DOI: https://doi.org/10.4103/psychiatry.IndianJPsychiatry_383_18
R. Pérez-Esparza, N. Oñate-Cadena, J. Ramírez-Bermúdez, M. Espínola-Nadurille, Valproate-induced hyperammonemic encephalopathy presenting as catatonia, Neurologist, 23(2), 51-52 (2018). DOI: https://doi.org/10.1097/NRL.0000000000000166
C. Lewis, G.E. Tesar, R. Dale, Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders, Psychosomatics, 58(4), 415- 420 (2017). DOI: https://doi.org/10.1016/j.psym.2017.02.003
M. Schou, Lithium in psychiatric therapy and prophylaxis, J. Psychiatr. Res., 6, 67-95 (1968). DOI: https://doi.org/10.1016/0022-3956(68)90047-2
A.S.H. Leung, Lithium carbonate, Can. Psychiatric Assoc. J., 15(2), 189-200 (1970). DOI: https://doi.org/10.1177/070674377001500213
R.P. Hullin, J.C. Swinscoe, R. McDonald, G.A. Dransfield, Metabolic balance studies on the effect of lithium salts in manic-depressive psychosis, Br. J. Psychiatry, 114(517), 1561-1573 (1968). DOI: https://doi.org/10.1192/bjp.114.517.1561
R. Epstein, L. Grant, M. Herjanic, G. Winokur, Urinary excretion of lithium in mania, J. Am. Med. Assoc., 192(5), 409 (1965). 53. K. Greenspan, R. Green, J. Durell, Retention and distribution patterns of lithium, a pharmacological tool in studying the pathophysiology of manicdepressive psychosis, Am. J. Psychiatry, 125(4), 512-519 (1968). DOI: https://doi.org/10.1176/ajp.125.4.512
M.E. Ward, M.N. Musa, L. Bailey, Clinical pharmacokinetics of lithium, J. Clin. Pharmacol., 34, 280-285 (1994). 55. G. Sanacora, New understanding of mechanisms of action of bipolar medications, J. Clin. Psychiatry, 69(Suppl. 5), 22-27 (2008).
J.F.J. Cade, Lithium salts in the treatment of psychotic excitement, Bull. World Health Organ., 78, 518-520 (2000).
G.S. Malhi, D. Gessler, T. Outhred, The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines, J. Affect. Disord., 217, 266-280 (2017). DOI: https://doi.org/10.1016/j.jad.2017.03.052
E. Won, Y.K. Kim, An oldie but goodie: Lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms, Int. J. Mol. Sci., 18(12), 2679 (2017). 59. R. Gong, P. Wang, L. Dworkin, What we need to know about the effect of lithium on the kidney, Am. J. Physiol. – Ren. Physiol., 311(6), F1168-F1171 (2016). DOI: https://doi.org/10.3390/ijms18122679
J. Davis, M. Desmond, M. Berk, Lithium and nephrotoxicity: A literature review of approaches to clinical management and risk stratification, BMC Nephrol., 19(1), 305 (2018). DOI: https://doi.org/10.1186/s12882-018-1101-4
M. Gitlin, Lithium side effects and toxicity: prevalence and management strategies, Int. J. Bipolar Disord., 4, 27 (2016). DOI: https://doi.org/10.1186/s40345-016-0068-y
L. Ambrosiani, C. Pisanu, A. Deidda, C. Chillotti, M.E. Stochino, A. Bocchetta, T hyroid and renal tumors in patients treated with long-term lithium: case series from a lithium clinic, review of the literature and international pharmacovigilance reports, Int. J. Bipolar Disord., 6(1), 17 (2018). DOI: https://doi.org/10.1186/s40345-018-0125-9
M.Á. Marín-Gabriel, A.M. Malalana-Martínez, I. Olza-Fernández, [Lithium while breastfeeding: Case report], Arch. Argent. Pediatr., 116(2), 319-321 (2018).
N.M. Stall, J.S. Zipursky, J. Rangrej, A. Jones, A.P. Costa, M.P. Hillmer, K. Brown, Assessment of psychotropic drug prescribing among nursing home residents in Ontario, Canada, during the Covid-19 pandemic, J. Am. Med. Assoc., Intern. Med., 181(6), 861-863 (2021). DOI: https://doi.org/10.1001/jamainternmed.2021.0224
M. Sabe, O. Dorsaz, P. Huguelet, S. Kaiser, Toxicity of psychotropic drugs in patients with Covid-19: A systematic review, Gen. Hosp. Psychiatry, 70, 1-9 (2021). DOI: https://doi.org/10.1016/j.genhosppsych.2021.02.006
C.A. Carrajo-García, E.B. Alonso-Sánchez, D. Hernández-Huerta, J. GómezArnau, Covid-19 treatment-induced neuropsychiatric adverse effects, Gen. Hosp. Psychiatry, 67, 163-164 (2020). DOI: https://doi.org/10.1016/j.genhosppsych.2020.06.001
N. Mohebbi, A. Talebi, M. Moghadamnia, Z. Nazari-Taloki, A. Shakiba, Drug interactions of psychiatric and Covid-19 medications, Basic Clin. Neurosci., 11(2), 185-200 (2020). DOI: https://doi.org/10.32598/bcn.11.covid19.2500.1
T. Gerstner, D. Buesing, E. Longin, Valproic acid induced encephalopathy 19 new cases in Germany from 1994 to 2003 a side effect associated to VPA-therapy not only in young children, Seizure, 15, 443-448 (2006). DOI: https://doi.org/10.1016/j.seizure.2006.05.007
V. Gayam, A.K. Mandal, Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review, J. Commun. Hosp. Int. Med. Perspect., 8, 311-314 (2018). DOI: https://doi.org/10.1080/20009666.2018.1514933
Z. Fan, L. Chen, J. Li, X. Cheng, J. Yang, C. Tian, Clinical features of Covid19-related liver functional abnormality, Clin. Gastroenterol. Hepatol., 18, 15611566 (2020). DOI: https://doi.org/10.1016/j.cgh.2020.04.002
E.A.K. Schaefer, A. Arvind, P.P. Bloom, R.T. Chung, Interrelationship between coronavirus infection and liver disease, Clin. Liver Dis., 15, 175-180 (2020). DOI: https://doi.org/10.1002/cld.967
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.
Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13
